Iñigo Rúa-Figueroa1, Francisco Javier López-Longo2, Jaime Calvo-Alén3, María Galindo-Izquierdo4, Estíbaliz Loza5, M Jesús García de Yebenes5, José M Pego-Reigosa6. 1. Servicio de Reumatología, Hospital Doctor Negrín, Las Palmas de Gran Canaria, España. Electronic address: iruafer@gobiernodecanarias.org. 2. Servicio de Reumatología, Hospital Gregorio Marañón, Madrid, España. 3. Servicio de Reumatología, Hospital Sierrallana, Torrelavega, España. 4. Servicio de Reumatología, Hospital 12 de Octubre, Madrid, España. 5. Unidad de Investigación de la SER, Madrid, España. 6. Servicio de Reumatología, Hospital Meixoeiro, Vigo, España.
Abstract
OBJECTIVE: To describe the objectives, design and methods of the Spanish Society of Rheumatology systemic lupus erythematosus (SLE) registry (RELESSER). METHODS: Multicenter, hospital-based registry, with retrospective collection of data from a large representative sample of adult patients with SLE (1997 ACR criteria) attending Spanish rheumatology services. The registry includes demographic data, frequent and infrequent (<1%) clinical manifestations, information about activity, damage, severity, comorbidity, treatments and mortality, collecting 359 variables per patient, with highly standardized definitions. We performed a preliminary descriptive analysis of the data. RESULTS: Forty-five centers were involved and 4,024 SLE patients (91% with ≥ 4 ACR criteria) have been included; 90% are women and 93% caucasians, with a median age at diagnosis of 33 years, median disease duration: 120 months, median follow-up duration: 104 months; 3,222 (81%) of the patients are in active follow-up and 591 (14%) were lost to follow-up. The median values of the SELENA-SLEDAI score, SLICC/ACR damage index and Katz severity index have been 2, 1 and 2, respectively. A total of 211 patients (6%) died. CONCLUSIONS: RELESSER represents the largest European SLE registry built to date, providing comprehensive and reliable information on SLE manifestations, disease status, comorbid conditions and treatments in daily clinical practice. RELESSER is constituted as a tool of great potential for multicenter clinical research in SLE.
OBJECTIVE: To describe the objectives, design and methods of the Spanish Society of Rheumatology systemic lupus erythematosus (SLE) registry (RELESSER). METHODS: Multicenter, hospital-based registry, with retrospective collection of data from a large representative sample of adult patients with SLE (1997 ACR criteria) attending Spanish rheumatology services. The registry includes demographic data, frequent and infrequent (<1%) clinical manifestations, information about activity, damage, severity, comorbidity, treatments and mortality, collecting 359 variables per patient, with highly standardized definitions. We performed a preliminary descriptive analysis of the data. RESULTS: Forty-five centers were involved and 4,024 SLEpatients (91% with ≥ 4 ACR criteria) have been included; 90% are women and 93% caucasians, with a median age at diagnosis of 33 years, median disease duration: 120 months, median follow-up duration: 104 months; 3,222 (81%) of the patients are in active follow-up and 591 (14%) were lost to follow-up. The median values of the SELENA-SLEDAI score, SLICC/ACR damage index and Katz severity index have been 2, 1 and 2, respectively. A total of 211 patients (6%) died. CONCLUSIONS: RELESSER represents the largest European SLE registry built to date, providing comprehensive and reliable information on SLE manifestations, disease status, comorbid conditions and treatments in daily clinical practice. RELESSER is constituted as a tool of great potential for multicenter clinical research in SLE.
Authors: Lucía Echevarría-Lucas; José Mᵃ Senciales-González; María Eloísa Medialdea-Hurtado; Jesús Rodrigo-Comino Journal: Int J Environ Res Public Health Date: 2021-07-05 Impact factor: 3.390
Authors: Íñigo Rúa-Figueroa; Patricia Richi; Francisco Javier López-Longo; María Galindo; Jaime Calvo-Alén; Alejandro Olivé-Marqués; Estíbaliz Loza-Santamaría; Sabina Pérez Vicente; Celia Erausquin; Eva Tomero; Loreto Horcada; Esther Uriarte; Ana Sánchez-Atrio; José Rosas; Carlos Montilla; Antonio Fernández-Nebro; Manuel Rodríguez-Gómez; Paloma Vela; Ricardo Blanco; Mercedes Freire; Lucía Silva; Elvira Díez-Álvarez; Mónica Ibáñez-Barceló; Antonio Zea; Javier Narváez; Víctor Martínez-Taboada; José Luis Marenco; Mónica Fernández de Castro; Olaia Fernández-Berrizbeitia; José Ángel Hernández-Beriain; Marian Gantes; Blanca Hernández-Cruz; José J Pérez-Venegas; Ángela Pecondón; Carlos Marras; Patricia Carreira; Gema Bonilla; Vicente Torrente; Iván Castellví; Juan Alegre; Mireia Moreno; Enrique Raya; Paloma García de la Peña; Tomás Vázquez; Ángeles Aguirre; Víctor Quevedo; José M Pego-Reigosa Journal: Medicine (Baltimore) Date: 2015-01 Impact factor: 1.889
Authors: Natalia Mena-Vázquez; Antonio Fernández-Nebro; José María Pego-Reigosa; María Galindo; Ana Melissa-Anzola; Esther Uriarte-Isacelay; Alejandro Olivé-Marqués; Elena Aurrecoechea; Mercedes Freire; Eva Tomero; María Jesús García-Villanueva; Claudia Stoye; Esteban Salas-Heredia; Jose Antonio Bernal-Vidal; Eva Salgado; Ricardo Blanco; Francisco Javier Novoa; Mónica Ibáñez-Barcelo; Vicente Torrente-Segarra; Javier Narvaez; Joan Calvet; Clara Moriano Morales; Tomas Ramon Vazquez-Rodriguez; Paloma Garcia de la Peña; Cristina Bohórquez; José Luis Andreu-Sánchez; Tatiana Cobo-Ibañez; Gema Bonilla; Nuria Lozano-Rivas; Carlos Montilla; Francisco Javier Toyos; Jose Luis Marenco De la Fuente; Lorena Expósito; María Esther Ruiz-Lucea; Elia Vals; Javier Manero-Ruiz; Jose A Bernal-Vidal; Iñigo Rua-Figueroa Journal: Rheumatology (Oxford) Date: 2020-08-01 Impact factor: 7.580
Authors: Javier Narváez; Helena Borrell; Fernando Sánchez-Alonso; Iñigo Rúa-Figueroa; Francisco Javier López-Longo; María Galindo-Izquierdo; Jaime Calvo-Alén; Antonio Fernández-Nebro; Alejandro Olivé; José Luis Andreu; Víctor Martínez-Taboada; Joan Miquel Nolla; José María Pego-Reigosa Journal: Arthritis Res Ther Date: 2018-12-19 Impact factor: 5.156
Authors: Beatriz Tejera Segura; Iñigo Rua-Figueroa; Jose Maria Pego-Reigosa; Victor Del Campo; Chris Wincup; David Isenberg; Anisur Rahman Journal: BMJ Open Date: 2019-06-14 Impact factor: 2.692
Authors: Antonio Fernández-Nebro; Íñigo Rúa-Figueroa; Francisco J López-Longo; María Galindo-Izquierdo; Jaime Calvo-Alén; Alejandro Olivé-Marqués; Carmen Ordóñez-Cañizares; María A Martín-Martínez; Ricardo Blanco; Rafael Melero-González; Jesús Ibáñez-Rúan; José Antonio Bernal-Vidal; Eva Tomero-Muriel; Esther Uriarte-Isacelaya; Loreto Horcada-Rubio; Mercedes Freire-González; Javier Narváez; Alina L Boteanu; Gregorio Santos-Soler; José L Andreu; José M Pego-Reigosa Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.817
Authors: María Galindo-Izquierdo; Esther Rodriguez-Almaraz; José M Pego-Reigosa; Francisco J López-Longo; Jaime Calvo-Alén; Alejandro Olivé; Antonio Fernández-Nebro; Víctor Martinez-Taboada; Paloma Vela-Casasempere; Mercedes Freire; Francisco J Narváez; José Rosas; Mónica Ibáñez-Barceló; Esther Uriarte; Eva Tomero; Antonio Zea; Loreto Horcada; Vicenç Torrente; Iván Castellvi; Joan Calvet; Raúl Menor-Almagro; María A Aguirre Zamorano; Enrique Raya; Elvira Díez-Álvarez; Tomás Vázquez-Rodríguez; Paloma García de la Peña; Atusa Movasat; José L Andreu; Patricia Richi; Carlos Marras; Carlos Montilla-Morales; Blanca Hernández-Cruz; José L Marenco de la Fuente; María Gantes; Eduardo Úcar; Juan J Alegre-Sancho; Javier Manero; Jesús Ibáñez-Ruán; Manuel Rodríguez-Gómez; Víctor Quevedo; José Hernández-Beriaín; Lucía Silva-Fernández; Fernando Alonso; Sabina Pérez; Iñigo Rúa-Figueroa Journal: Medicine (Baltimore) Date: 2016-03 Impact factor: 1.889
Authors: Maria Cevey; Jaime Calvo-Alén; Carlos Crespo; Angel Robles-Marhuenda; Lee Smolen; Josefina Cortés-Hernández Journal: Clinicoecon Outcomes Res Date: 2019-12-05